Tandem Isotope Therapy with<sup>225</sup>Ac- and<sup>177</sup>Lu-PSMA-617 in a Murine Model of Prostate Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Tandem Isotope Therapy with²²⁵Ac- and¹⁷⁷Lu-PSMA-617 in a Murine Model of Prostate Cancer

Published:2023-10-05 Issue:11 Volume:64 Page:1772-1778
ISSN:0161-5505
Container-title:Journal of Nuclear Medicine
language:en
Short-container-title:J Nucl Med

Author:

Meyer Catherine,Stuparu Andreea,Lueckerath Katharina,Calais Jeremie,Czernin Johannes,Slavik Roger,Dahlbom Magnus

Publisher

Society of Nuclear Medicine

Subject

Radiology, Nuclear Medicine and imaging

Reference49 articles.

1. MIRD: Radionuclide Data and Decay Schemes

2. Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches;Awang;Radiat Oncol.,2018

3. Radioligand Therapy With 177Lu-PSMA-617 as A Novel Therapeutic Option in Patients With Metastatic Castration Resistant Prostate Cancer

4. PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617

5. German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single Chelator–Minibody Theranostic Agents for⁸⁹Zr PET Imaging and¹⁷⁷Lu Radiopharmaceutical Therapy of PSMA-Expressing Prostate Cancer;Journal of Nuclear Medicine;2024-08-14

2. DNA Damage and Repair in PBMCs after Internal Ex Vivo Irradiation with [223Ra]RaCl2 and [177Lu]LuCl3 Mixtures;International Journal of Molecular Sciences;2024-08-07

3. Future Treatment Strategies for Cancer Patients Combining Targeted Alpha Therapy with Pillars of Cancer Treatment: External Beam Radiation Therapy, Checkpoint Inhibition Immunotherapy, Cytostatic Chemotherapy, and Brachytherapy;Pharmaceuticals;2024-08-05

4. 225Ac-PSMA-617 Augmentation in High-Risk mCRPC Undergoing 177Lu-PSMA-617 Radioligand Therapy;Clinical Nuclear Medicine;2024-05-21

5. Highlight selection of radiochemistry and radiopharmacy developments by editorial board;EJNMMI Radiopharmacy and Chemistry;2024-05-16

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3